Former Secretary Enrique Ona stated his successor on the Division of Well being is “solely accountable” for the dengue vaccination program utilizing the Dengvaxia vaccine.
“Within the gentle of the Sanofi Pasteur advisory on the usage of the antidengue vaccine Dengvaxia, the management that took over the DOH after I left in December 20, 2014 is solely answerable for all the choices that has resulted in what’s turning into to be a serious well being nightmare within the nation right now,” Ona stated in an announcement.
Ona was Secretary of Well being for 4 and a half years, from June 2010 to December 2014.
“Throughout this era, the Sanofi Pasteur Pharma group would request a briefing for me on the standing of the medical trial of their anti-dengue vaccine being examined (section three trial) in Southeast Asia, together with the Philippines, in addition to a number of nations in South America. This occurred nearly yearly throughout my time period as Secretary,” he stated.
In line with him, it was of nice curiosity to him since dengue fever will not be solely rampant within the Philippines, nearly showing all yr spherical, and was additionally getting used as one of many “measures of our public well being efficiency” by the general public.
“I had excessive hopes, like many others, that the vaccine being developed would finally management this mosquito-borne illness that afflicts greater than 100 thousand Filipinos (sufferers) yearly and scares so many international guests and vacationers,” the previous well being chief stated.
Sadly, he added, throughout all this time till the tip of his time period, the Sanofi workers, although optimistic, by no means claimed that the vaccine was prepared for common use.
Ona stated the pharmaceutical agency solely gave a imprecise projection to him of the time when it might be prepared for launching.
“I recall in multiple event that I discussed in passing to then President Aquino of a attainable dengue vaccine that possibly prepared ‘anytime quickly’,” he stated.
“Nonetheless, we didn’t allocate any funds for dengue vaccine for 2016 since I thought of this vaccine as nonetheless at its ‘developmental stage’ and was present process additional statement and analysis,” he confused.
Ona stated he was already out of the federal government in 2016 when he first heard that the DOH was going to buy the dengue vaccine to be given to youngsters above 9 years previous.
“And allocating a number of billion pesos, an quantity greater than your entire funds for all different vaccines being procured by the DOH yearly,” he added.
“It might be related …. to quote an article at one of many world’s most revered and credible journals, the New England Journal of Medication, September 24, 2015 concern which concluded: the efficacy profile at 25 months of illness surveillance was advanced — efficacy brought on by serotype 2 ranged from 67-80 % and decrease nonetheless for individuals who had been seronegative at baseline,” Ona stated.
He stated the report got here with a separate accompanying editorial entitled “A Candidate Dengue Vaccine Walks a Tightrope” by Cameron P. Simmons, Ph.D.
“If learn by any skilled in infectious ailments or public well being would have made one watch for extra observe up research to additional consider the security and efficacy, sans value. In brief, ‘worth for cash,’ so important in right now’s well being setting,” he added. /je
Subscribe to INQUIRER PLUS to get entry to The Philippine Each day Inquirer & different 70+ titles, share as much as 5 devices, take heed to the information, obtain as early as 4am & share articles on social media. Name 896 6000.